Serum bone resorption markers and 25-hydroxyvitamin D level in women of the Trans-Baikal region of the Russian and Buryat nationalities

Osteoporosis (OP) is a metabolic bone disease, characterized by a decrease of bone mineral density, leading to the development of low-energy fractures. Serum pyridinoline (PYD) and C-terminal cross-linking telopeptide type I (β-CrossLaps) are among the specific markers of bone resorption. Vitamin D is involved in the metabolism of bone tissue, its deficiency accelerates the processes of bone tissue breakdown. Material and methods. 60 women with osteoporosis were studied (30 Russian and 30 Buryat nationalities) aged 50 to 80 years; the control group included 20 women (10 Russian and 10 Buryat nationalities). Serum bone resorption markers, namely pyridinoline and β-CrossLaps, 25-hydroxyvitamin D (25(OH)D) were measured using immunoassays. Results and discussion. The level of β-CrossLaps was higher and the content of 25(OH)D was lower in women with osteoporosis compared to the control group. There was a positive relationship between β-CrossLaps concentration and body mass index < 20 kg/cm2 , frequent falls, and a hip fracture, between the level of 25(OH)D and hereditary history of osteoporosis in Russian women. There was a positive relationship between Serum pyridinoline and smoking, between 25(OH)D and low physical activity, β-CrossLaps and the major osteoporotic fractures in Buryat women. It was found that the β-CrossLaps is an independent predictor of the development of fractures in Russian women (β = 0.678, p = 0.04). In Buryat women, independent predictors of fractures are pyridinoline (β = –0.38, p = 0.04) and β-CrossLaps (β = 0.671, p = 0.01). Conclusions. The systemic markers of bone resorption (pyridinoline, β-CrossLaps) and 25(OH)D can be used in the diagnosis of osteoporosis and fractures in residents of the Trans-Baikal Region in addition to risk factor assessment and bone mineral density measurement. 

1. Clinical guidelines. Osteoporosis. 2021. Available at: https://www.endocrincentr.ru/sites/default/files/ specialists/science/clinic-recomendations/osteoporoz. pdf [In Russian].

2. Kanis J.A., Norton N., Harvey N.C., Jacobson T., Johansson H., Lorentzon M., McCloskey E.V., Willers C., Borgström F. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arc. Osteoporosis 2021;16(1):82. doi:10.1007/s11657-020-00871-9

3. Dobrovolskaya O.V., Toportsova N.V., Lesnyak O.M. Economic aspects of complicated osteoporosis: the cost of treatment in the first year after fracture. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(3):29–34. [In Russian]. doi: 10.14412/1996-7012-2016-3-29-34

4. Dzyuba G.G., Stasenko I.N., Kendys T.N., Irbagimova N.A. Assessment of the quality of life in patients with fractures – markers of osteoporosis (observational study). Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2020;23(1):104. [In Russian].

5. Mawatari T., Ikemura S., Matsui G., Iguchi T., Mitsuyasu H., Kawahara S., Maehara M., Muraoka R., Iwamoto Y., Nakashima Y. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial. Bone Rep. 2020;12:100275. doi: 10.1016/j.bonr.2020.100275

6. Qu X.L., Zheng B., Chen T.Y., Cao Z.R., Qu B., Jiang T. Bone turnover markers and bone mineral density to predict osteoporotic fractures in older women: a retrospective comparative study. Orthop. Surg. 2020;12(1):116–123. doi: 10.1111/os.12596

7. Marques E.A., Gudnason V., Lang T., Sigurdsson G., Sigurdsson S., Aspelund T., Siggeirsdottir K., Launer L., Eiriksdottir G., Harris T.B. Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study. Osteoporos Int. 2016;27(12):3485–3494. doi: 10.1007/ s00198-016-3675-7

8. Clinical guidelines. Vitamin D deficiency in adults. 2021. Available at: https://rae-org.ru/system/ files/documents/pdf/d_2021.pdf [In Russian].

9. Mudrov V.A. Statistical analysis algorithms of quantitative features in biomedical researchusing the SPSS software package. Zabaykal’skiy meditsinskiy vestnik = The Transbaikalian Medical Bulletin. 2020;(1):140–150. [In Russian]. doi: 10.52485/19986173_2020_1_140

10. Masheyko I.V. Biochemical markers for the evaluation of bone tissue remodeling in osteopenia and osteoporosis. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta = Journal of the Grodno State Medical University. 2017;15(2):149–153. [In Russian].

11. Maylyan E.A., Ignatenko G.A., Reznichenko N.A. Levels of hormones and markers of bone metabolism in postmenopausal osteoporosis. Medikosotsial’nyye problemy sem’i = Medical and Social Problems of the Family. 2018;23(1):41–48. [In Russian].

12. Vasilyeva L.V., Bezzubtseva E.N., Evstratova E.F., Gosteva E.V., Zubkova I.B. Clinical significance of genetic and inflammatory markers of bone metabolism in patients with chronic obstructive pulmonary disease and osteoporosis. Farmateka = Pharmateca. 2021;28(5):69–75. doi: 10.18565/pharmateca.2021.5.69-75. [In Russian].

13. Shigdel R., Osima M., Ahmed L.A., Joakimsen R.M., Eriksen E.F., Zebaze R., Bjørnerem Å. Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures. Bone. 2015;81:1–6. doi: 10.1016/j.bone.2015.06.016

14. Ignatiev A.M., Turchin N.I. Instrumental and biochemical indicators of the bone tissue state in osteomalacia and osteoporosis. Travma = Trauma. 2020;21(6):16–20. [In Russian]. doi: 10.22141/1608- 1706.6.21.2020.223883

15. Fan J., Li N., Gong X., He L. Serum 25-hydroxyvitamin D, bone turnover markers and bone mineral density in postmenopausal women with hip fractures. Clin. Chim. Acta. 2018;477:135–140. doi: 10.1016/j.cca.2017.12.015

16. Dai Z., Wang R., Ang L.W., Yuan J.M., Koh W.P. Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population. Bone. 2016;83:171– 177. doi: 10.1016/j.bone.2015.11.005

17. Adunts A.G., Reznichenko N.A., Simrok V.V., Rumyantseva Z.S., Kostetskaya N.I., Anikin S.S. Associations of the VDR gene polymorphisms rs1544410 and rs10735810 with several indicators of blood serum in the dynamics of postmenopausal osteoporosis treatment. Tavricheskiy Medico-biologicheskiy vestnik = Tauric Medico-Biological Bulletin. 2020;23(3):6–13. [In Russian]. doi: 10.37279/2070-8092-2020-23-3-6-13

18. Crandall C.J., Vasan S., LaCroix A., LeBoff M.S., Cauley J.A., Robbins J.A., Jackson R.D., Bauer D.C. Bone turnover markers are not associated with hip fracture risk: a case-control study in the women’s health initiative. J. Bone. Miner. Res. 2018;33(7):1199– 1208. doi: 10.1002/jbmr.3471

19. Nor Hashimah A.M.M., Sakthiswary R., Shaharir S.S., Wahab A. Serum pyridinoline is associated with radiographic joint erosions in rheumatoid arthritis. Arch. Rheumatol. 2019;34(4):387–394. doi: 10.5606/ ArchRheumatol.2019.7243

20. Kalahasthi R., Barman T., Bagepally B.S. Assessment of bone turnover biomarkers in lead-battery workers with long-term exposure to lead. Int. J. Occup. Environ. Med. 2020;11(3):140–147. doi: 10.34172/ijoem.2020.1951

21. Wanby P., Nobin R., Von S.P., Brudin L., Carlsson M. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls. J. Endocrinol. Invest. 2016;39(8):855–863. doi: 10.1007/s40618-015-0421-5

22. Liu C., Kuang X., Li K., Guo X., Deng Q., Li D. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2020;11(12):10817– 10827. doi: 10.1039/d0fo00787k